Catalyst Pharm Inc (CPRX) 0.76 $CPRX
Catalyst Pharmaceuticals to Hold Second Quarter Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 10th, 2016
GlobeNewswire - Mon Aug 01, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it will release Second Quarter 2016 financial results after market close on Tuesday, August 9, 2016. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. EDT on Wednesday, August 10th, 2016 to discuss the financial results and to provide a corporate update.
CPRX: 0.76 (+0.04)
Catalyst Pharmaceuticals (CPRX) Jumps: Stock Rises 6.6%
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 7:25AM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) moved big last session, as its shares jumped almost 7% on the day.
CPRX: 0.76 (+0.04), JNP: 7.50 (-0.04)
Catalyst Pharmaceuticals Announces Agreement with FDA on Confirmatory Phase 3 Study Protocol for Firdapse in Lambert-Eaton Myasthenic Syndrome
GlobeNewswire - Mon Jun 13, 7:07AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a confirmatory Phase 3 study protocol for Firdapse(R) (amifampridine phosphate) for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS). As part of the clinical protocol for the confirmatory study, Catalyst expects to initiate a small, single-center study with Firdapse during the second half of 2016. Catalyst also expects to announce additional information about the study design and timelines for the study once they are finalized.
CPRX: 0.76 (+0.04)
Technical Analysis on Drugs - Generic Equities -- Akorn, Ironwood Pharma, Catalyst Pharma, and Pacira Pharma
PR Newswire - Fri Jun 10, 7:00AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by accessing their free trade alerts at:
IRWD: 13.94 (-0.19), CPRX: 0.76 (+0.04), AKRX: 33.80 (-0.43), PCRX: 37.58 (+1.33)
Catalyst Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the Company will be presenting at the Jefferies 2016 Healthcare Conference, in New York. Patrick J. McEnany, Catalyst's Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Tuesday, June 7 at 4:30 pm ET. The Company's presentation materials will be available on the "Investors" section of the Company's website, www.catalystpharma.com following the presentation.
CPRX: 0.76 (+0.04)
Catalyst (CPRX) Resorts to Layoffs for Firdapse Development
Zacks Equity Research - Zacks Investment Research - Wed May 18, 8:22AM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) announced that it will reduce its workforce by approximately 30%. The move will primarily affect the commercial team.
ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), CPRX: 0.76 (+0.04), PFE: 37.31 (+0.42)
Catalyst Pharmaceutical's Firdapse Phase 3 Study Published in Muscle & Nerve
GlobeNewswire - Wed May 18, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported on the publication of detailed results from the LMS-002 Phase 3 study of amifampridine phosphate (Firdapse(R)) in patients with Lambert-Eaton myasthenic syndrome (LEMS). The study results were published in the May 2016 issue of Muscle & Nerve (volume 53, number 5), authored by Dr. Shin Oh, et al.
CPRX: 0.76 (+0.04)
Catalyst Pharmaceuticals Announces Reduction in Workforce as Part of Operating Expense Management Plan
GlobeNewswire - Tue May 17, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the company is reducing its workforce by approximately 30%. The reduction in workforce, which affects employees from Catalyst's commercial team, is part of Catalyst's ongoing efforts to conserve cash as it works to complete the requirements for an NDA submission of Firdapse(R) (amifampridine phosphate) for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS).
CPRX: 0.76 (+0.04)
Catalyst (CPRX) Posts In-Line Q1 Loss, Firdapse in Focus
Zacks Equity Research - Zacks Investment Research - Wed May 11, 2:29PM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 7 cents per share in the first quarter of 2016, which was wider than the year-ago loss of 6 cents but in line with the Zacks Consensus Estimate.
ABT: 45.29 (+0.54), CPRX: 0.76 (+0.04), SHPG: 194.00 (-0.12), ARQL: 1.68 (+0.02)
Catalyst Pharmaceuticals Announces First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Tue May 10, 4:10PM CDT
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the first quarter ended March 31, 2016.
CPRX: 0.76 (+0.04)
Drug Stocks Reporting on May 10: XON, ARIA, CPRX & More
Zacks Equity Research - Zacks Investment Research - Mon May 09, 9:13AM CDT
What's in store for drug stocks, Jazz, Intrexon and others when they report their first-quarter results on May 10?
JNJ: 125.40 (+0.17), CPRX: 0.76 (+0.04), JAZZ: 150.53 (-0.44), XON: 27.38 (+2.05), AMGN: 174.16 (+2.13), ANAC: 99.06 (-0.14), ARIA: 9.71 (+0.20)
What's in the Cards for Catalyst (CPRX) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 11:18AM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) is scheduled to report first-quarter 2016 results on May 10.
IPXL: 31.15 (-0.27), CPRX: 0.76 (+0.04), JAZZ: 150.53 (-0.44), XON: 27.38 (+2.05)
Catalyst Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Wednesday, May 11th, 2016
GlobeNewswire - Fri May 06, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it will release First Quarter 2016 financial results after market close on Tuesday, May 10, 2016. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. EDT on Wednesday, May 11, 2016 to discuss the financial results and to provide a corporate update.
CPRX: 0.76 (+0.04)
Penny Stocks To Watch on Friday April 29
ACCESSWIRE - Fri Apr 29, 11:58AM CDT
MIAMI, FL / ACCESSWIRE / April 29, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. FREEF, KEG, CPRX, and HUSA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
CPRX: 0.76 (+0.04), KEG: 0.16 (-0.01)
The Zacks Analyst Blog Highlights: Biogen, Sarepta, Catalyst Pharmaceuticals, AbbVie and Gilead
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Sarepta, Catalyst Pharmaceuticals, AbbVie and Gilead
BIIB: 301.83 (+11.90), GILD: 80.46 (+0.99), CPRX: 0.76 (+0.04), SRPT: 25.91 (+0.63), ABBV: 66.94 (+0.71)
Biotech Stock Roundup: Biogen Tops on Q1 Earnings, Sarepta, Catalyst Plunge on Regulatory News
Arpita Dutt - Zacks Investment Research - Wed Apr 27, 3:07PM CDT
While most major biotech stocks will be reporting results this week, Biogen (BIIB) kick-started the earnings season for the sector with an earnings beat.
BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), CPRX: 0.76 (+0.04), GILD: 80.46 (+0.99), SRPT: 25.91 (+0.63), ABBV: 66.94 (+0.71), REGN: 434.00 (+8.88)
Why Is Catyalyst Pharma (CPRX) Stock Crashing Today?
Ryan McQueeney - Zacks Investment Research - Tue Apr 26, 12:18PM CDT
Catalyst Pharmaceuticals (CPRX) stock crashed over 50% after the company announced that the FDA has requested additional data in its resubmission of a new drug application for Firdapse, a treatment for Lambert-Eaton myasthenic syndrome.
CPRX: 0.76 (+0.04)
Catalyst Pharmaceuticals Provides Regulatory Update on Firdapse
GlobeNewswire - Tue Apr 26, 5:55AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today provided an update on the content of the planned resubmission of the New Drug Application ("NDA"
for Firdapse(R) (amifampridine phosphate), which currently has Breakthrough Therapy and Orphan Drug designations for Lambert-Eaton myasthenic syndrome (LEMS). Catalyst recently met with the Food and Drug Administration ("FDA" to obtain greater clarity regarding what will be required by the FDA to accept the Firdapse NDA for filing.
CPRX: 0.76 (+0.04)
Catalyst (CPRX) Posts In-Line Q4 Loss, FDA Meeting in Focus
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 3:29PM CDT
Catalyst Pharmaceuticals (CPRX) reported a loss of 7 cents per share in fourth-quarter 2015, wider than the year-ago loss of 5 cents but in line with the Zacks Consensus Estimate.
CPRX: 0.76 (+0.04), SCMP: 11.89 (+0.14), CORT: 5.77 (-0.03)
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2015 Financial Results
GlobeNewswire - Tue Mar 15, 3:30PM CDT
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the fourth quarter and the year-ended December 31, 2015.
CPRX: 0.76 (+0.04)
Catalyst Pharmaceuticals to Hold Second Quarter Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 10th, 2016
GlobeNewswire - Mon Aug 01, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it will release Second Quarter 2016 financial results after market close on Tuesday, August 9, 2016. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. EDT on Wednesday, August 10th, 2016 to discuss the financial results and to provide a corporate update.
CPRX: 0.76 (+0.04)
Catalyst Pharmaceuticals (CPRX) Jumps: Stock Rises 6.6%
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 7:25AM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) moved big last session, as its shares jumped almost 7% on the day.
CPRX: 0.76 (+0.04), JNP: 7.50 (-0.04)
Catalyst Pharmaceuticals Announces Agreement with FDA on Confirmatory Phase 3 Study Protocol for Firdapse in Lambert-Eaton Myasthenic Syndrome
GlobeNewswire - Mon Jun 13, 7:07AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a confirmatory Phase 3 study protocol for Firdapse(R) (amifampridine phosphate) for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS). As part of the clinical protocol for the confirmatory study, Catalyst expects to initiate a small, single-center study with Firdapse during the second half of 2016. Catalyst also expects to announce additional information about the study design and timelines for the study once they are finalized.
CPRX: 0.76 (+0.04)
Technical Analysis on Drugs - Generic Equities -- Akorn, Ironwood Pharma, Catalyst Pharma, and Pacira Pharma
PR Newswire - Fri Jun 10, 7:00AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by accessing their free trade alerts at:
IRWD: 13.94 (-0.19), CPRX: 0.76 (+0.04), AKRX: 33.80 (-0.43), PCRX: 37.58 (+1.33)
Catalyst Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the Company will be presenting at the Jefferies 2016 Healthcare Conference, in New York. Patrick J. McEnany, Catalyst's Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Tuesday, June 7 at 4:30 pm ET. The Company's presentation materials will be available on the "Investors" section of the Company's website, www.catalystpharma.com following the presentation.
CPRX: 0.76 (+0.04)
Catalyst (CPRX) Resorts to Layoffs for Firdapse Development
Zacks Equity Research - Zacks Investment Research - Wed May 18, 8:22AM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) announced that it will reduce its workforce by approximately 30%. The move will primarily affect the commercial team.
ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), CPRX: 0.76 (+0.04), PFE: 37.31 (+0.42)
Catalyst Pharmaceutical's Firdapse Phase 3 Study Published in Muscle & Nerve
GlobeNewswire - Wed May 18, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported on the publication of detailed results from the LMS-002 Phase 3 study of amifampridine phosphate (Firdapse(R)) in patients with Lambert-Eaton myasthenic syndrome (LEMS). The study results were published in the May 2016 issue of Muscle & Nerve (volume 53, number 5), authored by Dr. Shin Oh, et al.
CPRX: 0.76 (+0.04)
Catalyst Pharmaceuticals Announces Reduction in Workforce as Part of Operating Expense Management Plan
GlobeNewswire - Tue May 17, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the company is reducing its workforce by approximately 30%. The reduction in workforce, which affects employees from Catalyst's commercial team, is part of Catalyst's ongoing efforts to conserve cash as it works to complete the requirements for an NDA submission of Firdapse(R) (amifampridine phosphate) for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS).
CPRX: 0.76 (+0.04)
Catalyst (CPRX) Posts In-Line Q1 Loss, Firdapse in Focus
Zacks Equity Research - Zacks Investment Research - Wed May 11, 2:29PM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 7 cents per share in the first quarter of 2016, which was wider than the year-ago loss of 6 cents but in line with the Zacks Consensus Estimate.
ABT: 45.29 (+0.54), CPRX: 0.76 (+0.04), SHPG: 194.00 (-0.12), ARQL: 1.68 (+0.02)
Catalyst Pharmaceuticals Announces First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Tue May 10, 4:10PM CDT
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the first quarter ended March 31, 2016.
CPRX: 0.76 (+0.04)
Drug Stocks Reporting on May 10: XON, ARIA, CPRX & More
Zacks Equity Research - Zacks Investment Research - Mon May 09, 9:13AM CDT
What's in store for drug stocks, Jazz, Intrexon and others when they report their first-quarter results on May 10?
JNJ: 125.40 (+0.17), CPRX: 0.76 (+0.04), JAZZ: 150.53 (-0.44), XON: 27.38 (+2.05), AMGN: 174.16 (+2.13), ANAC: 99.06 (-0.14), ARIA: 9.71 (+0.20)
What's in the Cards for Catalyst (CPRX) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 11:18AM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) is scheduled to report first-quarter 2016 results on May 10.
IPXL: 31.15 (-0.27), CPRX: 0.76 (+0.04), JAZZ: 150.53 (-0.44), XON: 27.38 (+2.05)
Catalyst Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Wednesday, May 11th, 2016
GlobeNewswire - Fri May 06, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it will release First Quarter 2016 financial results after market close on Tuesday, May 10, 2016. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. EDT on Wednesday, May 11, 2016 to discuss the financial results and to provide a corporate update.
CPRX: 0.76 (+0.04)
Penny Stocks To Watch on Friday April 29
ACCESSWIRE - Fri Apr 29, 11:58AM CDT
MIAMI, FL / ACCESSWIRE / April 29, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. FREEF, KEG, CPRX, and HUSA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
CPRX: 0.76 (+0.04), KEG: 0.16 (-0.01)
The Zacks Analyst Blog Highlights: Biogen, Sarepta, Catalyst Pharmaceuticals, AbbVie and Gilead
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Sarepta, Catalyst Pharmaceuticals, AbbVie and Gilead
BIIB: 301.83 (+11.90), GILD: 80.46 (+0.99), CPRX: 0.76 (+0.04), SRPT: 25.91 (+0.63), ABBV: 66.94 (+0.71)
Biotech Stock Roundup: Biogen Tops on Q1 Earnings, Sarepta, Catalyst Plunge on Regulatory News
Arpita Dutt - Zacks Investment Research - Wed Apr 27, 3:07PM CDT
While most major biotech stocks will be reporting results this week, Biogen (BIIB) kick-started the earnings season for the sector with an earnings beat.
BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), CPRX: 0.76 (+0.04), GILD: 80.46 (+0.99), SRPT: 25.91 (+0.63), ABBV: 66.94 (+0.71), REGN: 434.00 (+8.88)
Why Is Catyalyst Pharma (CPRX) Stock Crashing Today?
Ryan McQueeney - Zacks Investment Research - Tue Apr 26, 12:18PM CDT
Catalyst Pharmaceuticals (CPRX) stock crashed over 50% after the company announced that the FDA has requested additional data in its resubmission of a new drug application for Firdapse, a treatment for Lambert-Eaton myasthenic syndrome.
CPRX: 0.76 (+0.04)
Catalyst Pharmaceuticals Provides Regulatory Update on Firdapse
GlobeNewswire - Tue Apr 26, 5:55AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today provided an update on the content of the planned resubmission of the New Drug Application ("NDA"
for Firdapse(R) (amifampridine phosphate), which currently has Breakthrough Therapy and Orphan Drug designations for Lambert-Eaton myasthenic syndrome (LEMS). Catalyst recently met with the Food and Drug Administration ("FDA" to obtain greater clarity regarding what will be required by the FDA to accept the Firdapse NDA for filing. CPRX: 0.76 (+0.04)
Catalyst (CPRX) Posts In-Line Q4 Loss, FDA Meeting in Focus
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 3:29PM CDT
Catalyst Pharmaceuticals (CPRX) reported a loss of 7 cents per share in fourth-quarter 2015, wider than the year-ago loss of 5 cents but in line with the Zacks Consensus Estimate.
CPRX: 0.76 (+0.04), SCMP: 11.89 (+0.14), CORT: 5.77 (-0.03)
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2015 Financial Results
GlobeNewswire - Tue Mar 15, 3:30PM CDT
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the fourth quarter and the year-ended December 31, 2015.
CPRX: 0.76 (+0.04)
